复星医药：枸橼酸伏维西利胶囊新增适应症获批准

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for a new indication for the drug citric acid vorinostat capsules, aimed at treating hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer in adult patients [1] Group 1 - The newly approved indication is for use in combination with aromatase inhibitors as initial endocrine therapy [1]